Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
MMED fell 6% on the week to $18.40, and the earnings report that was meant to resolve the short thesis has instead left bears more entrenched, with another earnings event now days away.
The borrow market is as tight as it has been all year. Availability has fallen to effectively zero, just 0.0001%, meaning every share in the lending pool is already lent out. That is unchanged from Monday, and it comes after a cost-to-borrow reading that leapt to 196.7% on Tuesday, more than four times the 44.8% recorded the previous session and nearly thirty times where it stood six weeks ago. Short interest itself reached 27.2 million shares on October 13, up 6% on the day and 19% over the past week. To put the scale of the build in context: a month ago there were roughly 7.4 million shares short. The ORTEX short score has eased slightly from its peak of 93.6 on October 6 to 88.9, but has not broken below 89 in the ten days shown, a sustained extreme rather than a momentary spike. The FINRA settlement figure from September 30 counted 18.2 million shares short. Bears have added materially since the earnings print, not covered into it.
Options traders continue to lean the other way. The put/call ratio is 0.95, slightly below its 20-day mean of 1.01 and roughly 0.3 standard deviations under it. That is close to neutral, but it marks a real shift from a month ago, when the ratio sat above 1.3 and options positioning was clearly defensive. The rotation toward calls has persisted even as the stock fell and the borrow market deteriorated further. The divergence between the lending desk and the options desk that defined the pre-earnings setup has not resolved: both camps have simply become somewhat less extreme, while the fundamental disagreement remains.
The Street is divided in a way that mirrors the positioning split. Analyst consensus is a hold, but the target range tells the real story. Jefferies initiated at Hold with a $22 target this week, and Barclays set the same number on initiation last week. Mizuho is more constructive, raising its target to $28 and maintaining Outperform. Truist started coverage at Buy with a $29 target in September. The mean target is $24.64, roughly 34% above the current price. Bulls point to the full-stack diabetes franchise spanning pumps, CGMs, smart pens and pharmacy fulfillment, with Q1 organic revenue growth of 15.8%, CGM attachment near 69%, and adjusted EBITDA expected to nearly double by FY29. Bears counter that growth is slower than peers, that stand-up costs from the Medtronic separation limit near-term margin expansion, and that the company's dependence on Abbott for CGM supply adds concentration risk. The PE multiple has compressed sharply, down more than 6 points over the past month to 27.2x, and EV/EBITDA has drifted lower to 7.6x, both reflecting the stock's 18% fall from a month ago.
The ownership structure adds another layer of context. Medtronic holds 89.9% of shares outstanding under a Schedule 13G filing, leaving very little free float in outside hands. That structural scarcity is almost certainly amplifying the borrow constraints: with most shares held by a single strategic owner not lending into the market, shorts are competing for a thin pool. Independent institutional holders are modest in size, with Massachusetts Financial Services the largest at under 3% of shares. BlackRock and Geode both added positions as of September 30, but neither holds more than 0.7%.
The next catalyst is close. MMED has another earnings event scheduled for October 16. After the October 9 print, the stock fell 5% on the day. The September 1 report produced a 17% single-day gain. With cost to borrow at 197%, borrow availability at the floor, and short interest at its highest level in the short history of this listed entity, the question heading into Thursday is whether the lending market can sustain its current configuration or whether any change in price direction forces a rapid unwind.
See the live data behind this article on ORTEX.
Open MMED on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
